scholarly journals GENETIC SUBTYPE GUIDED RITUXIMAB‐BASED IMMUNOCHEMOTHERAPY IMPROVES OUTCOME IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA: FIRST REPORT OF A RANDOMIZED PHASE 2 STUDY

2021 ◽  
Vol 39 (S2) ◽  
Author(s):  
M Zhang ◽  
P Xu ◽  
L Wang ◽  
S Cheng ◽  
W Zhao
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Phase 2 ◽  
Newly Diagnosed ◽  
Large B Cell Lymphoma ◽  
Genetic Subtype ◽  
Phase 2 Study ◽  
Randomized Phase 2 ◽  
Large B Cell

scholarly journals FDG-PET–driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study

Blood ◽  
2017 ◽  
Vol 130 (11) ◽  
pp. 1315-1326 ◽  
Author(s):  
R.-O. Casasnovas ◽  
L. Ysebaert ◽  
C. Thieblemont ◽  
E. Bachy ◽  
P. Feugier ◽  
...  
Keyword(s):  
B Cell ◽  
Fdg Pet ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Phase 2 ◽  
Large B Cell Lymphoma ◽  
Phase 2 Study ◽  
Key Points ◽  
Randomized Phase 2 ◽  
Large B Cell

Key Points Superiority of R-ACVBP over R-CHOP14 was not established, as IHP criteria driving consolidation did not properly reflect disease control. The 26% PET2−/PET4− patients using IHP criteria increased to 79% using ΔSUVmax, which may help better select those needing an alternative to SIC.

A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma

2015 ◽  
Vol 57 (1) ◽  
pp. 216-218 ◽  
Author(s):  
John D. Hainsworth ◽  
Edward R. Arrowsmith ◽  
Michael McCleod ◽  
Eric D. Hsi ◽  
Oday Hamid ◽  
...  
Keyword(s):  
High Risk ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Phase 2 ◽  
Large B Cell Lymphoma ◽  
Phase 2 Study ◽  
Randomized Phase 2 ◽  
Large B Cell

Phase 2 Study of Dose-Reduced Consolidation Radiation Therapy in Diffuse Large B-Cell Lymphoma

2019 ◽  
Vol 105 (1) ◽  
pp. 96-101 ◽  
Author(s):  
Chris R. Kelsey ◽  
Gloria Broadwater ◽  
Olga James ◽  
Junzo Chino ◽  
Louis Diehl ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Phase 2 ◽  
Large B Cell Lymphoma ◽  
Phase 2 Study ◽  
Large B Cell

A phase 2 study of PNT2258 in patients with relapsed or refractory (r/r) diffuse large b-cell lymphoma (DLBCL): An initial report from the Wolverine study.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. TPS7577-TPS7577 ◽  
Author(s):  
Jason R. Westin ◽  
Michael B. Maris ◽  
Ayad M. Al-Katib ◽  
Nehal J. Lakhani ◽  
Prapti Arvind Patel ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Phase 2 ◽  
Initial Report ◽  
Large B Cell Lymphoma ◽  
Phase 2 Study ◽  
Large B Cell

Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 3039-3039 ◽  
Author(s):  
Frederick Lundry Locke ◽  
Armin Ghobadi ◽  
Lazaros J. Lekakis ◽  
David Bernard Miklos ◽  
Caron A. Jacobson ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Phase 2 ◽  
Pivotal Phase ◽  
Large B Cell Lymphoma ◽  
Phase 2 Study ◽  
Large B Cell
Sign in / Sign up

Export Citation Format

Share Document